Superficial urinary bladder carcinoma

Researchers are testing whether drug testing in patient-derived organoids can guide chemotherapy for low-grade non-muscle invasive bladder cancer. Adults with primary or recurrent low-grade bladder cancer receive one of four chemo drugs, epirubicin, mitomycin C, gemcitabine, or d…

This phase 2 trial is testing an experimental drug called RAG-01, either alone or combined with chemotherapy, in people with a type of bladder cancer that hasn't spread into the muscle layer. The study aims to see if the drug can improve how long patients go without their cancer …

This study tests whether adding chemotherapy drugs (gemcitabine and mitomycin C) directly into the bladder alongside an immune-boosting drug (toripalimab) works better than toripalimab alone for people with a high-risk bladder cancer that did not respond to standard BCG therapy. …

This phase III trial tests whether giving the drug Alpha1H directly into the bladder before standard surgery lowers the risk of cancer returning in adults with low- to intermediate-risk non-muscle-invasive bladder cancer. Participants are randomly assigned to receive either six A…

This Phase 3 trial tests NDV-01, a sustained-release combination of two chemotherapy drugs (gemcitabine and docetaxel), given directly into the bladder. It aims to prevent cancer from coming back in people with non-muscle invasive bladder cancer, including those who have not resp…

This trial tests a new tool called CURTIS, designed to safely remove bladder tumors in one intact piece after they are cut out during surgery. The goal is to see how often the device can successfully retrieve the tumor without breaking it apart, and what the largest tumor size is…

This trial is testing a device that delivers heated chemotherapy directly into the bladder for people with non-muscle invasive bladder cancer. The goal is to see if the system is safe and works as intended. Participants will receive the treatment and be monitored for side effects…

This trial asks whether some people with intermediate-risk bladder cancer can safely skip chemotherapy after having their tumor removed. Doctors will use a urine test before surgery to find patients whose tumors are unlikely to shed detectable signals. These patients will then be…

This trial tests whether a newer surgical method called en bloc resection, which removes bladder tumors in one piece, works better than the standard piecemeal approach for people with intermediate- or high-risk non-muscle-invasive bladder cancer. All participants also receive a y…

This study tests a treatment called HIVEC, which delivers heated chemotherapy directly into the bladder. It is for people with a type of bladder cancer that has not responded to standard therapy and who cannot have their bladder removed. The goal is to see if this approach is saf…

This phase 2 trial tests a virus-based drug given directly into the bladder for people with high-risk non-muscle invasive bladder cancer. The virus is designed to attack cancer cells and trigger the immune system. About 18 participants will receive increasing doses to find the sa…

This phase 3 trial compares radiotherapy with a radiosensitiser to the standard BCG immunotherapy for high-risk non-muscle invasive bladder cancer. About 328 patients will be randomly assigned to one of the two treatments after tumor removal. The goal is to see which approach bet…

This trial tests whether a fluorescent dye called TTP-ICG, which targets a protein found on bladder cancer cells, can help surgeons spot tumors during surgery. People with suspected or confirmed non-muscle invasive bladder cancer will have the dye placed into their bladder before…

Researchers are testing whether heated saline can be safely given during surgery to remove early bladder tumors. The study enrolls adults with small papillary tumors that have not grown into the bladder muscle. Participants receive either heated saline or room-temperature saline …

This trial tests a personalized home-based supportive care program for people with non-muscle-invasive bladder cancer who receive intravesical perfusion therapy after surgery. The program provides physical symptom relief, psychological support, and education to help patients mana…

This study tests a newer, more precise radiation method (adaptive radiotherapy) for people with muscle-invasive bladder cancer who cannot have surgery or choose not to. The goal is to see if this technique reduces bowel side effects like diarrhea compared to standard radiation. A…

This study looks at the well-being and medical care of people in Korea who had their bladder removed (radical cystectomy) for bladder cancer. Using nationwide insurance records, researchers will track complications, hospital stays, readmissions, and survival up to three years aft…